Xponance Inc. lowered its stake in Amazon.com, Inc. (NASDAQ:AMZN - Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,087,397 shares of the e-commerce giant's stock after selling 114,700 shares during the quarter. Amazon.com makes up 3.6% of Xponance Inc.'s investment portfolio, making the stock its 4th largest position. Xponance Inc.'s holdings in Amazon.com were worth $458,330,000 as of its most recent filing with the Securities & Exchange Commission. Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Amazon.com by 10.9% in the 4th quarter. Brighton Jones LLC now owns 4,036,091 shares of the e-commerce giant's stock worth $885,478,000 after buying an additional 397,007 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Amazon.com by 4.1% in the fourth quarter. Revolve Wealth Partners LLC now owns 25,045 shares of the e-commerce giant's stock worth $5,495,000 after buying an additional 986 shares during the period. Bank Pictet & Cie Europe AG lifted its stake in shares of Amazon.com by 2.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 2,016,869 shares of the e-commerce giant's stock valued at $442,481,000 after acquiring an additional 54,987 shares during the last quarter. Highview Capital Management LLC DE boosted its holdings in Amazon.com by 5.5% during the 4th quarter. Highview Capital Management LLC DE now owns 28,975 shares of the e-commerce giant's stock valued at $6,357,000 after acquiring an additional 1,518 shares during the period. Finally, Liberty Square Wealth Partners LLC bought a new position in Amazon.com during the 4th quarter worth approximately $2,153,000. Institutional investors own 72.20% of the company's stock. Get Amazon.com alerts: Sign Up Trending Headlines about Amazon.com Here...

中国人民银行召开经济金融专家座谈会，潘功胜表示，大家提出了很多具有建设性的意见建议。今年以来，中国人民银行坚决贯彻落实党中央、国务院决策部署，在存量政策接续发挥作用的基础上，又发布了涉及结构性货币政策工具的若干调整项，适度宽松的货币政策取得较好成效，有力提振市场信心、稳定社会预期。下一阶段，中国人民银行将全面贯彻落实党的二十届四中全会、中央经济工作会议精神和《政府工作报告》部署要求，构建科学稳健的货币政策体系，继续实施好适度宽松的货币政策，加大逆 周期（883436） 和跨 周期（883436） 调节力度，为经济持续向好向优创造适宜的货币金融环境。（央行）

Xponance Inc. lessened its stake in shares of NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 2.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,938,487 shares of the computer hardware maker's stock after selling 160,363 shares during the period. NVIDIA comprises about 8.8% of Xponance Inc.'s holdings, making the stock its biggest position. Xponance Inc.'s holdings in NVIDIA were worth $1,108,003,000 as of its most recent filing with the SEC. A number of other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its position in shares of NVIDIA by 1.0% in the second quarter. State Street Corp now owns 978,208,862 shares of the computer hardware maker's stock valued at $154,556,803,000 after acquiring an additional 9,554,857 shares during the period. Geode Capital Management LLC increased its stake in NVIDIA by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 579,213,497 shares of the computer hardware maker's stock worth $91,150,170,000 after acquiring an additional 8,521,936 shares during the last quarter. Norges Bank purchased a new stake in shares of NVIDIA in the 2nd quarter valued at about $51,386,863,000. Legal & General Group Plc boosted its position in shares of NVIDIA by 1.5% during the 2nd quarter. Legal & General Group Plc now owns 178,593,475 shares of the computer hardware maker's stock valued at $28,215,983,000 after acquiring an additional 2,623,678 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of NVIDIA by 2.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 155,668,775 shares of the computer hardware maker's stock worth $24,594,110,000 after purchasing an additional 4,209,423 shares in the last quarter. Hedge funds and other institutional investors own 65.27% of the company's stock. Get NVIDIA alerts: Sign Up Trending Headline...

Telligent Fund LP raised its holdings in NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 22.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,000 shares of the computer hardware maker's stock after buying an additional 8,000 shares during the period. NVIDIA comprises approximately 7.0% of Telligent Fund LP's investment portfolio, making the stock its biggest holding. Telligent Fund LP's holdings in NVIDIA were worth $8,210,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Winnow Wealth LLC acquired a new position in shares of NVIDIA in the second quarter valued at approximately $32,000. Longfellow Investment Management Co. LLC raised its stake in NVIDIA by 47.9% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 207 shares of the computer hardware maker's stock worth $33,000 after purchasing an additional 67 shares in the last quarter. Spurstone Advisory Services LLC bought a new stake in NVIDIA in the 2nd quarter valued at about $40,000. Sellwood Investment Partners LLC bought a new position in shares of NVIDIA during the third quarter worth approximately $50,000. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new stake in shares of NVIDIA in the second quarter valued at approximately $54,000. 65.27% of the stock is currently owned by institutional investors. Get NVIDIA alerts: Sign Up Wall Street Analysts Forecast Growth Several analysts have recently issued reports on the company. Tigress Financial reissued a "strong-buy" rating and set a $360.00 target price (up from $350.00) on shares of NVIDIA in a report on Thursday, March 5th. BNP Paribas Exane lifted their price objective on shares of NVIDIA from $260.00 to $270.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. DZ Bank reaffirmed a "buy" rating on shar...

Xponance Inc. decreased its holdings in Apple Inc. (NASDAQ:AAPL - Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,673,887 shares of the iPhone maker's stock after selling 128,731 shares during the period. Apple comprises approximately 7.4% of Xponance Inc.'s portfolio, making the stock its 3rd largest position. Xponance Inc.'s holdings in Apple were worth $935,482,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Financial Futures Ltd Liability Co. boosted its holdings in shares of Apple by 13.2% in the second quarter. Financial Futures Ltd Liability Co. now owns 3,552 shares of the iPhone maker's stock valued at $729,000 after acquiring an additional 415 shares during the period. Monarch Capital Management Inc. grew its stake in shares of Apple by 4.6% in the 2nd quarter. Monarch Capital Management Inc. now owns 66,967 shares of the iPhone maker's stock valued at $13,740,000 after purchasing an additional 2,920 shares during the last quarter. Riverwater Partners LLC raised its stake in shares of Apple by 17.9% during the second quarter. Riverwater Partners LLC now owns 5,404 shares of the iPhone maker's stock worth $1,109,000 after purchasing an additional 819 shares during the last quarter. Highland Capital Management LLC raised its stake in shares of Apple by 2.2% during the third quarter. Highland Capital Management LLC now owns 397,834 shares of the iPhone maker's stock worth $101,301,000 after purchasing an additional 8,446 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its holdings in shares of Apple by 48.4% during the third quarter. Citizens Financial Group Inc. RI now owns 1,426,605 shares of the iPhone maker's stock worth $363,256,000 after purchasing an additional 465,393 shares during ...

Virtus Wealth Solutions LLC lowered its stake in NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 4.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 278,896 shares of the computer hardware maker's stock after selling 13,992 shares during the period. NVIDIA makes up approximately 10.0% of Virtus Wealth Solutions LLC's holdings, making the stock its 4th biggest position. Virtus Wealth Solutions LLC's holdings in NVIDIA were worth $52,036,000 as of its most recent SEC filing. A number of other institutional investors have also made changes to their positions in the stock. Brighton Jones LLC raised its holdings in NVIDIA by 12.4% in the 4th quarter. Brighton Jones LLC now owns 324,901 shares of the computer hardware maker's stock worth $43,631,000 after acquiring an additional 35,815 shares during the period. Bank Pictet & Cie Europe AG increased its stake in shares of NVIDIA by 1.0% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 2,346,417 shares of the computer hardware maker's stock worth $315,100,000 after purchasing an additional 22,929 shares during the period. Highview Capital Management LLC DE boosted its stake in NVIDIA by 6.7% during the 4th quarter. Highview Capital Management LLC DE now owns 58,396 shares of the computer hardware maker's stock valued at $7,842,000 after purchasing an additional 3,653 shares during the period. Hudson Value Partners LLC grew its holdings in NVIDIA by 30.7% in the 4th quarter. Hudson Value Partners LLC now owns 50,658 shares of the computer hardware maker's stock valued at $6,805,000 after buying an additional 11,900 shares during the last quarter. Finally, Wealth Group Ltd. increased its position in NVIDIA by 15.7% in the 1st quarter. Wealth Group Ltd. now owns 6,598 shares of the computer hardware maker's stock worth $715,000 after buying an additional 896 shares during the period. 65.27% of the stock is owned by institutional inves...

Whalerock Point Partners LLC cut its holdings in NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 1.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 328,940 shares of the computer hardware maker's stock after selling 5,675 shares during the period. NVIDIA accounts for about 12.5% of Whalerock Point Partners LLC's portfolio, making the stock its largest holding. Whalerock Point Partners LLC's holdings in NVIDIA were worth $61,374,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Winnow Wealth LLC purchased a new position in shares of NVIDIA during the 2nd quarter worth approximately $32,000. Longfellow Investment Management Co. LLC boosted its position in shares of NVIDIA by 47.9% during the second quarter. Longfellow Investment Management Co. LLC now owns 207 shares of the computer hardware maker's stock worth $33,000 after buying an additional 67 shares during the period. Spurstone Advisory Services LLC acquired a new stake in shares of NVIDIA in the second quarter valued at $40,000. Sellwood Investment Partners LLC acquired a new stake in shares of NVIDIA in the third quarter valued at $50,000. Finally, EDENTREE ASSET MANAGEMENT Ltd acquired a new position in NVIDIA during the 2nd quarter worth about $54,000. Hedge funds and other institutional investors own 65.27% of the company's stock. Get NVIDIA alerts: Sign Up NVIDIA Stock Performance Shares of NVDA opened at $186.00 on Thursday. The stock has a 50 day moving average price of $185.59 and a 200 day moving average price of $184.07. The company has a quick ratio of 3.24, a current ratio of 3.91 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $4.52 trillion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 0.63 and a beta of 2.33. NVIDIA Corporation has a 52-week low of $86.62 and a 52-week hi...

Dollar General (DG) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $1.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +19.71%. A quarter ago, it was expected that this discount retailer would post earnings of $0.92 per share when it actually produced earnings of $1.28, delivering a surprise of +39.13%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Dollar General, which belongs to the Zacks Retail - Discount Stores industry, posted revenues of $10.91 billion for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 1.17%. This compares to year-ago revenues of $10.3 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Dollar General shares have added about 9.1% since the beginning of the year versus the S&P 500's decline of 1%. What's Next for Dollar General? While Dollar General has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings ...

Electric vehicle drivers and smartphone power users have been salivating over the prospect of silicon anode batteries, which promise to dramatically boost energy density and lower charging times. Several companies have been working on silicon anodes over the last decade or so, and the tech has started creeping into consumer electronics. Wearable maker Whoop, for example, uses materials from Sila, while Group14‘s batteries can be found in a range of smartphones. But the real prize is the EV market, which dwarfs consumer electronics by an order of magnitude, according to Benchmark Minerals. To break into this space, however, startups need to produce silicon anode material in far larger quantities than they have been so far. To hit that scale, Group14 on Thursday said it had started production at its BAM-3 factory in South Korea. The facility is capable of producing up 2,000 metric tons of silicon battery materials annually, enough for 10 gigawatt-hours of energy storage, or about 100,000 long-range EVs. “It’s a big deal for us, and I think it’s a big deal for the industry, too,” Rick Luebbe, co-founder and CEO of Group14, told TechCrunch. The BAM-3 facility broke ground as a joint venture between Group14 and SK, the Korean battery manufacturer. SK owned 75% of the project, but sold its stake to Group14 last summer. “SK has had their own challenges — financial and reprioritizing their battery and battery materials strategies all at the same time,” Luebbe said. “It did open up a great opportunity for us to acquire it from SK.” Techcrunch event Disrupt 2026: The tech ecosystem, all in one room Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to $400. Save up to $300 or 30% to TechCrunch Founder Summit 1,000+ founders and investors come togeth...

is a senior reporter who’s been covering and reviewing the latest gadgets and tech since 2006, but has loved all things electronic since he was a kid. Posts from this author will be added to your daily email digest and your homepage feed. Karaoke is more fun for everyone when the person holding the mic sounds as good as a song’s original performer. So the latest addition to JBL’s PartyBox Bluetooth speaker line, the On-the-Go 2 Plus, comes with one of the company’s new EasySing wireless microphones, which use an algorithm to silence a song’s vocals while also helping a karaoke singer stay on pitch and hit more challenging high notes. The On-The-Go 2 Plus is now available for preorder from the company’s website for $419.95, with availability expected to start on April 5th. It’s an update to JBL’s original PartyBox On-The-Go speaker, and while it still delivers up to 100W of sound, there are some notable improvements. The newer model pairs a 5.25-inch woofer with two upgraded 20mm silk-dome tweeters, and its replaceable battery can now deliver up to 15 hours of playtime — more than double that of the previous model. The On-the-Go 2 Plus is available in black or white with a matching wireless microphone. Image: JBL The speaker’s portability has also been improved, with a flexible handle on top that’s more comfortable and a wider shoulder strap. It comes with Auracast support for syncing multiple units — a Bluetooth feature JBL has included for a while — and as with most party speakers (and the previous model), you’ll find interactive RGB LED lighting on the front that responds to the music being played. The EasySing wireless mic is available separately and works with older versions of JBL’s party speakers. Image: JBL But it’s the included EasySing wireless microphone that’s the On-the-Go 2 Plus’ most interesting feature. It connects to the speaker using a USB-C dongle and uses JBL’s EasySing Algorithm to reduce vocals from a song by 25 percent, 50 percent, or remove th...

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent corporate progress. “2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide (PEP™) platform,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity pipeline, built on our clinically validated PEPTM platform and designed for once-monthly dosing and improved tolerability. We look forward to a data-rich year ahead and to continuing our pursuit of bringing differentiated and best-in-class medicines to patients.” Fourth Quarter 2025 and Recent Corporate Highlights Once-Weekly Canvuparatide for Hypoparathyroidism (HP) End-of-Phase 2 FDA meeting for once-weekly canvuparatide completed: FDA feedback supported advancement into a Phase 3 trial and trial design elements have now been selected, including the number of patients, p...

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027 CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026 Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026 PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the full year ended December 31, 2025, and recent business highlights. “Century entered 2026 with strong momentum, fueled by the successful completion of our $135 million private placement and continued focus on advancing our prioritized programs closer to patients living with significant unmet medical need,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “We are moving fast and executing with precision on CNTY-813, our top priority and a program we believe has the potential to functionally cure type 1 diabetes. Recent achievements, including compelling preclinical results combined with constructive interactions with the FDA, strengthen our confidence in the clinical path ahead. We plan to submit an IND as early as the fourth quarter of this year and anticipate initial clinical data in the second half of 2027. We are energized by the progress across our pipeline, confident in the road ahead, and focused on advancing our most promising programs into the clinic.” Fourth Quarter 2025 and Recent Highlights Pipeline CNTY-813, priority program for type 1 diabetes, advancing through IND-enabling activities and tracking toward planned IND submission in 2026: C...

- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. “We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio while we remain focused on the advancement of our oncology pipeline,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “We continue to advance our lead oncolytic virus candidate VCN-01 towards pivotal clinical development in multiple indications of high unmet need. With the recent feedback from the EMA, we have further clarity on dosing regimen, protocol and overall design for our proposed Phase 3 trial in pancreatic ductal adenocarcinoma (PDAC). An End-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to finalize our design for a multinational pivotal Phase 3 trial in PDAC, aiming to provide patients with a novel therapy for this difficult to treat solid tumor that has a high mortality rate. Additional interactions with the FDA and EMA are planned for 2026 to refine the design of a potential Phase 2/3 trial for retinoblastoma, for which VCN-01 has received Orphan Drug and Rare Pediatric Disease designation. We continue to engage in potential partnership discuss...

AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per share (basic), in 2024. Net cash used in operations was $32.3 million in 2025, consistent with previous guidance. The Company met cash guidance for year-end 2025, reporting $95.5 million, and estimates cash at June 30, 2026 in a range from $47 to $50 million. The Company estimates net cash use in operations for first half of 2026 in a range from $14 to $17 million, plus a payment of a $31.25 million estimated loss contingency related to the potential settlement of certain securities litigation recorded in 2025. “At Filana Therapeutics, our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by the urgent need for new treatment options that can meaningfully improve patients’ lives,” said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. “In partnership with our advisors, we are working diligently to address the FDA’s requests and look forward to sharing a progress update in the coming months.” Corporate Updates: Name change to Filana Therapeutics, Inc.: Filana Therapeutics’ new name and brand reflect the Company’s strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of CNS disorders, such as TSC-related epi...

Dairy RNG production increased 61% year over year in Q4 2025; ethanol plant efficiency upgrade expected to increase plant cash flow from operations by approximately $32 million annually Aemetis Biogas segment net income increased to $12.2 million in Q4 2025 Aemetis Biogas segment increased annual revenues and production tax credits by 53% Dairy RNG production increased 61% year over year in Q4 2025 Aemetis Biogas achieved annual segment net income of $6.9 million Capital investments increased 28% over the prior year to $26.0 million, supporting dairy RNG expansion and ethanol plant energy efficiency upgrades Dairy digester projects generated cash proceeds of $18 million during 2025 from the sale of investment tax credits Ethanol and Biogas operations generated additional income of $10.4 million from production tax credits during the fourth quarter of 2025 MVR ethanol plant efficiency upgrade expected to increase cash flow from operations by approximately $32 million annually after completion in 2026 CUPERTINO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on low and negative carbon intensity products, today announced its financial results for the fourth quarter and year ending December 31, 2025. “Revenues for the full year of 2025 were $197.6 million plus production tax credit income of $10.4 million for total income of $208.0 million,” said Todd Waltz, Chief Financial Officer of Aemetis. “Capital expenditures for carbon intensity reduction and the expansion of biogas production capacity were $26 million for 2025 as our engineering and construction teams moved forward with low carbon initiatives and the dairy RNG project buildout,” added Waltz. "In addition to achieving important operational milestones during 2025 in all of the business segments, the dairy RNG segment generated net income of $12.2 million for the fourth quarter of 2025 while we continued building the infrastructur...

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 Oversubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDA Completion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027 SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2025 financial results and provided recent updates on its CNM-Au8 programs. “Our next key milestone is the upcoming Type C face-to-face meeting with the U.S. Food and Drug Administration (FDA) on Clene’s biomarker and survival data, which if positive, will facilitate filing of an new drug application (NDA) under an accelerated approval pathway for ALS by the end of the second quarter of 2026,” said Rob Etherington, President and CEO of Clene. “In parallel, we continue to advance plans to initiate our confirmatory Phase 3 trial in ALS, which is required to be “underway” by CNM-Au8 approval in ALS, as well as to continue working with the FDA on the initiation of a Phase 3 clinical trial using cognition as an endpoint in MS. Based on our combined findings to date, we continue to believe that patients across multiple neurodegenerative conditions may benefit from the improved mitochondrial function plus energy metabolism associated with CNM-Au8 treatment.” Fourth Quarter ...

Blackwell Ramp, Custom Accelerators, and Broad Component Demand to Drive 2026 Expansion REDWOOD CITY, Calif., March 12, 2026 /PRNewswire/ -- According to a recently published report by Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, the Data Center IT Components market continued to expand in 4Q 2025, supported by the ongoing deployment of large-scale AI infrastructure and strong demand across both AI and general-purpose data center components. Dell'Oro Group Logo. (PRNewsFoto/Dell'Oro Group) "Hyperscalers rapidly scaled AI infrastructure in 2025, driving strong demand not only for AI accelerators but also for the broader ecosystem of components supporting these deployments," said Baron Fung, Sr. Research Director at Dell'Oro Group. "NVIDIA's Blackwell platform continued scaling across major cloud providers, and we expect hyperscalers to begin transitioning to next-generation platforms Vera Rubin later this year. AMD's upcoming MI400 platform is also expected to ramp later this year, increasing diversity in the merchant accelerator market. In addition to Google and Amazon driving significant volumes for both internal and external consumption, other US and Chinese hyperscalers are expanding deployments of custom accelerators, particularly for inference workloads," said Fung. Additional highlights from the 4Q 2025 Data Center IT Semiconductors and Components Quarterly Report: NVIDIA led vendors in data center IT component revenue, followed by SK Hynix and Samsung. NVIDIA's performance reflected the strong ramp of the Blackwell platform, which includes GPUs, CPUs, and NICs. SK Hynix and Samsung benefited from surging HBM demand and rising DRAM and SSD prices. High-end accelerators will remain the largest contributor to revenue growth in 2026, supported by the launch of NVIDIA's Vera Rubin and AMD's MI400 rack-scale platforms, along with next-generation custom accelerators from Google...

VALENCIA, Spain, March 12, 2026 (GLOBE NEWSWIRE) -- Turbo Energy, S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of AI-optimized solar energy storage technologies and solutions, today announced that it has entered into a securities purchase agreement with a single global institutional investor for the purchase and sale of 1,000,000 of the Company’s American Depositary Shares (“ADSs”) at a purchase price of $3.25 per ADS in a registered direct offering. The gross proceeds from the offering are expected to be approximately $3.25 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about March 13, 2026, subject to the satisfaction of customary closing conditions. The financing strengthens the Company’s balance sheet and supports the continued expansion of Turbo Energy’s AI-driven solar energy storage and intelligent energy management solutions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The ADSs offered to the institutional investor described above are being offered pursuant to a registration statement on Form F-3 (File No. 333-291470), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 16, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus which are a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone ...

Lighthouse Films/DigitalVision via Getty Images Co-authored by Kody's Dividends How easy is it for you to forgive somebody? I mean truly forgive someone, as in forgive them and move on without constantly mentioning it or using it as ammo over their head. If we were honest with ourselves, the vast majority of us really struggle with forgiveness. We're good at saying the words. We're bad at living it out afterward. We like to hold grudges, to constantly bring up past failures to beat down someone who's trying to move forward, or use those past failures as leverage to force this person to do something they don't want to do. When it comes to investing, most investors are no better. There is a reason why the dividend cutters have statistically worse performance over the long run than those companies that initiate dividends or grow dividends. It's because investors are unforgiving. Aside from maybe some high-yield investors who see dividend cuts regularly and continue to buy or recommend the same companies over and over. Most investors are not willing to play with fire when it comes to their capital. What happens if a company hasn't been cutting its dividend, but just has become extremely expensive? Investors shouldn't just look at dividend growth and dividend yield to determine the value of a company. They need to look at what the company has traded hands for historically versus what it's trading hands for now. Investors can often get frustrated when they buy an overvalued company, and then that company's value returns from the sky back to earth. Many investors struggle with what I call "Icarus syndrome." I'll release an article in the future specifically discussing what this is. But in short, Icarus Syndrome is when we fly too high, whether we're buying too high of yields or too high valuations, and we suffer the consequences when we fall back to Earth. As an investor with decades of investment time left on my horizon and with most of my readers being investors with dec...

seewhatmitchsee/iStock Editorial via Getty Images Groupon, Inc. ( GRPN ) has been on a long slide. Since peaking a few bucks under $40 back in July of 2025, Groupon has fallen to just over $10. The latest earnings report fueled another selloff, but actually, I believe earnings were decent enough. Crucially, the company has resumed revenue growth, only a paltry 1% for FY 2025, but this lends hope that the company could be bottoming out. Data by YCharts I previously covered Groupon and also rated it a Hold then owing to declining revenues and a slightly high price. At the time I didn’t find it tempting even as a speculative bet. However, my outlook has improved a fair bit, and I can now justify speculative purchases. High risk, but high upside. Since speculative plays are fundamentally different than general investments, I don’t want to assign a Buy rating and accidentally mislead readers given the risks. Anyway, a big concern back then was slipping revenues. Now, revenues are starting to tick up. The slide in share price also makes the prices more attractive. What I did like about Groupon the last time I looked is the belief that it can perform well with so many consumers under pressure. That remains true now. I’ll jump into the earnings results and fundamentals first, then revisit why consumers under pressure bode well for GRPN. GRPN: Earnings and Valuation Consideration Groupon’s relevancy has come under question for some time. Revenues, as shown below, have been collapsing. In FY 2024 , revenues shrank about 4% to $492.6 million from a year prior. In 2025, revenue growth resumed, rising a mere 1% to total $498.4 million, but crucially, the slide has stopped. Whether it’s a temporary breather or a true bottoming out remains to be seen. Seeking Alpha Gross billings, meaning what customers are spending on the platform, were up 7% in FY 2025 to $1.7 billion from a year prior. In Q4 specifically, they were up 4% to $446.5 millon. In both cases, gross billings beat out ...

John M Lund Photography Inc/DigitalVision via Getty Images Listen here or on the go via Apple Podcasts and Spotify Scott Kaufman from The Dividend Kings explains the market's large rotation from growth focused investments to being overwhelmingly focused on value (0:35) Long-term structural shifts (2:00) Enbridge is overpriced (4:30) Software sell-off (5:30) Cashflow is king; Canadian National Resources, EOG Resources (7:00) Private credit selloff but no wide scale default (14:00) Bond yields remain low (18:00) Transcript Rena Sherbill: Scott Kaufman from The Dividend Kings . Welcome back to Investing Experts. Always great to talk to you. Scott Kaufman: Thank you so much for having me. Always great to come in. Rena Sherbill: Not many people talking about dividends these past couple of weeks, I would say, since war has started and a lot of people talking about oil and energy and a lot of different things. Not many people talking about dividends. How are you thinking about dividends in this particular time? Scott Kaufman: Dividend investing interestingly has had quite the run over the last few months. If we look at even like the Schwab dividend ETFs, the big ones like ( SCHD ), where last year it returned about 4 % over the whole year, but it's up 12 % year to date. We're seeing a large rotation from heavily growth focused investments that were really focused on like the buy anything kind of AI trade over to investments that are overwhelmingly focused on value. To the point now where we're actually seeing PE ratios that are close to what used to be growth investment PE ratios in the value space. And so we're now seeing an overextension where investors are pouring from one side into the other and now overextending what used to be good investments. And the same is going on with the war, right? Oil prices are gyrating like crazy over whether or not oil is going to be able to go through that one specific Strait or not. And so we're seeing a lot of folks rotate from one to ...

hapabapa/iStock Editorial via Getty Images After the market closed on March 11th, the management team at Bumble ( BMBL ) announced results covering the final quarter of the company's 2025 fiscal year. The picture for the firm was certainly mixed. However, with management promising margin expansion and continued product innovation, shares of the business rose in after-hours trading. And they didn't just rise a bit. As of this writing, they are up 18.7%. This surge might seem peculiar given the fact that revenue and the number of users actually fell pretty significantly year over year. But when you look at just how cheap the stock is and some of the cash flow improvements that the company exhibited, it makes sense that there would be optimism at this moment. To be clear, the company is certainly a risky prospect. I don't like seeing the number of users decline after years of expansion. But considering how cheap the stock is, both on an absolute basis and relative to other similar firms, I would argue that enough upside potential exists relative to the risk that this opportunity involves that investors should take it seriously. A Good Match for the Right Investor Although I have never used the service, I do know through word of mouth that Bumble operates as one of the most successful dating platforms out there. The company can actually be described best as a collection of apps. Specifically, it has its Bumble, Bumble For Friends, Badoo, Geneva, Fruitz, and Official apps. At the end of 2024, this ecosystem of apps had more than 42 million users on a monthly basis. And just like many of the platforms that are out there, they operate on a freemium model where certain base functionality is free and costs are only borne by a small number of paying users. The most significant of its apps is Bumble, which was launched in 2014 and serves as a major dating app centered around women making the first move. However, the Badoo app is no slouch. It's actually a bit older, having bee...

Two U.S. senators are proposing supersized standard deductions to shrink people’s tax bills.

"AI-Powered Recipe App Gains Momentum with Top 50 Ranking in Apple's Food & Drink Category, Growing Social Media Buzz, and Upcoming Nationwide Campaign" MESA, AZ / ACCESS Newswire / March 12, 2026 / Medical Care Technologies Inc. today announced that its AI-powered mobile application Snapshot Recipes has generated its first revenue, marking an important milestone for the company's expanding portfolio of artificial intelligence applications. The achievement represents the company's first successful monetization of its AI technology within the consumer smart device ecosystem. Medical Care Technologies Inc. Snapshot Recipes, available on both the Google Play Store and the Apple App Store, has quickly gained traction with users and food enthusiasts. The app recently ranked in the Top 50 in the Food & Drink category on iOS for nearly two consecutive weeks after peaking at #11, highlighting strong early adoption and growing user engagement. The app is also gaining significant attention across social media platforms including TikTok and Instagram, where food lovers and creators are showcasing visually appealing recipes and discovering new meals through the platform's AI-powered tools. Snapshot Recipes can be explored at www.snapshotrecipes.app. Snapshot Recipes leverages artificial intelligence to help users create, discover, and recreate meals with ease. The application represents the first in a planned suite of AI-powered lifestyle and wellness apps being developed by Medical Care Technologies Inc. "Generating our first revenue from Snapshot Recipes represents a major milestone for Medical Care Technologies and validates our strategy of bringing AI-driven applications directly to consumers through smart devices," said Marshall Perkins. "The early traction we are seeing-from strong rankings in the iOS Food & Drink category to rapidly growing social engagement-demonstrates the demand for innovative AI-powered tools that enhance everyday experiences. This milestone is only ...

AUSTIN, Texas, March 12, 2026 /PRNewswire/ -- Oracle has been recognized as a leader in the IDC MarketScape: Worldwide AI-Enabled Embedded Trade Financing Applications 2025-2026 Vendor Assessment (doc # US52980825, December 2025). According to the report, businesses should "Consider Oracle when your organization requires a robust, scalable solution to digitize, unify, and automate trade finance operations powered by AI across geographies and complex product types." Oracle's Trade Finance suite is trusted by more than 200 banks in over 40 countries to operate faster, connect safely across ecosystems, and benefit from more interoperable trade finance. The report, assessed 14 trade finance solutions, evaluating each solution on criteria including scalability, compliance, and customization. To learn more, see an excerpt of the report here. "Oracle's Trade Finance solution suite is adept at automating and unifying trade finance solutions across multiple geographies, currencies, and entities," said Jordan Steele, research manager, IDC. "Amid mounting complexities in the global economic environment and the accelerated pace of digital transformation, Oracle emerges as a capable partner for financial institutions seeking sustainable and resilient AI-infused trade practices." The Oracle Banking Trade Finance suite recently earned the SWIFT Compatible Application Label for Trade Finance 2025, providing banks with the interoperability, standardization, and digital acceleration needed to drive efficiency, resilience, and growth in fragmented trade ecosystems. "We believe Oracle's recognition as a Leader in the IDC MarketScape report, combined with the SWIFT Compatible Application Label for Trade Finance 2025, underscores our commitment to delivering sector leading, AI-infused trade finance capabilities for banks and their corporate clients," said Sovan Shatpathy, senior vice president, product management and development, Oracle Financial Services. Our complete trade finance plat...

Oracle Permitting and Licensing streamlines processes for local businesses and citizens, while Oracle Fusion Cloud Applications deliver AI-enabled efficiencies AUSTIN, Texas, March 12, 2026 /PRNewswire/ -- The City of Miami has chosen Oracle Permitting and Licensing (OPAL) to improve public service delivery, and simplify processes for local residents and businesses. This selection expands on Miami's previous adoption of Oracle Fusion Cloud Applications for finance and HR, equipping the city with an integrated cloud platform for essential business processes. As Miami has grown, residents and businesses have faced significant challenges with outdated permitting processes that led to lengthy delays and unnecessary complexity. To address these challenges, the city sought a consolidated, user-friendly solution to automate review processes and offer readily accessible services for citizens and businesses. Miami chose Oracle Permitting and Licensing to deliver an even more consistent, unified IT experience for its operations and to transform its permitting and licensing operations. By moving to a single integrated suite of AI-powered cloud applications, Miami will be able to reduce technology debt, increase the speed and accuracy of finance and HR processes, and meet the ever-growing regulatory and economic development needs of the community. "From day one, I committed to fix Miami's broken permitting system, and I am proud that our team is making big strides towards that goal. This partnership with Oracle will transform how residents and businesses experience City Hall," said Miami mayor Eileen Higgins. "Accelerating permitting with the latest technologies can save residents time, money, and frustration. I am proud of our employees and commission for advancing these reforms." With Oracle Permitting and Licensing, Miami will consolidate services from multiple departments into a single system, improving transparency and progress tracking for citizens and employees. The AI-e...

Miami’s broken permitting system gets AI upgrade in new Oracle deal Stock Titan

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient strat

NEW YORK, March 12, 2026 /PRNewswire/ -- LivePerson (NASDAQ: LPSN), a leading provider of predictable conversational AI, today announced the launch of LivePerson Sync in partnership with Coral Active, a leader in enterprise contact center integrations. LivePerson Sync enables seamless integration with systems like Salesforce, Microsoft, and ServiceNow, bringing CRM data and workflows directly into the live agent workspace. LivePerson Logo (PRNewsfoto/LivePerson, Inc.) "LivePerson Sync is the answer brands have been looking for to improve agent productivity and experience by providing agents with the customer information they need in a single view," said John Sabino, LivePerson CEO. "By further connecting our agent workspace with critical information from across systems, we're removing the friction of disconnected systems." LivePerson Sync is partnering with Coral Active, a company founded in 2011 to improve live agent experiences by simplifying agent workspaces through integrations with contact centers, CRMs, and legacy applications. Bridging the Tech Stack Divide As brands grapple with increasingly complex technology stacks, live agents often lose critical time toggling between disconnected systems. LivePerson Sync addresses this challenge by providing a true single pane of glass experience. It allows brands to synchronize LivePerson Conversational Cloud with CRM, CCaaS, or browser-based applications in real-time. Key Capabilities of LivePerson Sync LivePerson Sync treats every interaction as a real-time event that can trigger automated workflows across multiple platforms. It offers four primary deployment models: CRM in LivePerson: Secure bidirectional customer profile data sync and lead/ticket management directly within the LivePerson workspace. LivePerson in CRM: A native chat capability embedded directly inside the enterprise's preferred CRM desktop, providing a seamless upgrade for legacy connectors. Context Synchronization: Context-aware synchronization that ...

Building on the success of the inaugural cohort, the program continues to accelerate startups building at the intersection of physical AI and robotics BOSTON, MA / ACCESS Newswire / March 12, 2026 / MassRobotics today announced the second cohort of the Physical AI Fellowship , a virtual program powered by Amazon Web Services (AWS) Startups and NVIDIA Inception that helps high-potential robotics startups build, refine, and scale physical AI solutions. Following the success of the inaugural Fall 2025 cohort, the 2026 cohort brings together nine promising startups advancing physical AI across agriculture, construction and renewable energy, industrial automation, retail and logistics, robotics data infrastructure, teleoperation, and wearable and humanoid robotics applications. Demand for physical AI continues to accelerate as industries seek to deploy intelligent machines in real-world environments. By providing startups with deep technical guidance, cloud and compute resources, and access to a global robotics ecosystem, the fellowship enables teams to move from promising prototypes to enterprise-grade deployments. "We're excited to launch our second Physical AI Fellowship cohort and continue working alongside industry leaders like AWS and NVIDIA to help startups scale real-world physical AI solutions," said Tom Ryden, Executive Director at MassRobotics. "We look forward to showcasing the cohort at the Robotics Summit & Expo in May and connecting them with the broader community during Boston Tech Week ." Meet the 2026 Cohort: Burro | Config | Deltia | Haply Robotics | Luminous Robotics | Roboto AI | Telexistence | Terra Robotics | WIRobotics The Physical AI Fellowship provides deep technical guidance, compute resources, and access to a global robotics ecosystem so teams can move from promising prototypes to enterprise-grade deployments. Fellows receive support from AWS Generative AI Innovation Center scientists and experts, and AWS credits. The Fellowship also provides ...